Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

Weight Loss FDA Approved

GLP-1 receptor agonist

Mechanism of Action

Activates GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite.

1,248
Community Posts
349
Users Discussing
1,345
Research Articles

Reported Outcomes

Clinical Strength: A (621 trials)

Based on community reports (1,248 posts). Grade reflects frequency and consistency of positive mentions.

B Weight Loss
233 mentions

Reduction in body weight

C Blood Sugar Control
147 mentions

Improved glycemic control and insulin sensitivity

C Sleep Quality
128 mentions

Effects on sleep quality

C Appetite Suppression
105 mentions

Reduced hunger and food cravings

D Mental/Mood
59 mentions

Effects on mood and cognitive function

D Body Composition
50 mentions

Changes in muscle vs fat ratio

D GI Health
62 mentions

Gastrointestinal effects

D Energy Levels
41 mentions

Changes in energy and fatigue levels

D Cardiovascular
27 mentions

Effects on heart health markers

Side Effects

Based on 271 user reports. Frequency indicates how often each was mentioned.

Common (>5%)

Nausea
Mild 50 reports 14.2%
Constipation
Mild 43 reports 12.2%
Fatigue
Mild 41 reports 11.6%
Food Noise
Mild 18 reports 5.1%

Uncommon (1-5%)

Insomnia
Mild 16 reports 4.5%
Stinging
Mild 14 reports 4.0%
Tiredness
Mild 11 reports 3.1%
Diarrhea
Mild 10 reports 2.8%
Hair Loss
Mild 10 reports 2.8%
Chills
Mild 10 reports 2.8%
Heartburn
Mild 9 reports 2.5%
Vomiting
Mild 9 reports 2.5%
Sickness
Mild 8 reports 2.3%
Headache
Mild 7 reports 2.0%
Injection Site Pain
Mild 7 reports 2.0%
Increased Hunger
Mild 7 reports 2.0%
Sleepiness
Mild 7 reports 2.0%
Burning
Mild 6 reports 1.7%
Sulfur Burps
Mild 6 reports 1.7%
Depression
Mild 6 reports 1.7%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

!

Pancreatitis

6 mentions

Rare but serious. Stop medication and seek care for severe persistent abdominal pain.

!

Thyroid Concerns

7 mentions

GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents. Contraindicated in MEN2 or personal/family history of MTC.

!

Gallbladder Issues

4 mentions

Rapid weight loss increases gallstone risk. Report severe abdominal pain to healthcare provider.

!

Hypoglycemia Risk

10 mentions

Risk increases when combined with insulin or sulfonylureas. Monitor blood sugar carefully.

!

Muscle Loss

5 mentions

Rapid weight loss may include muscle. Adequate protein intake and resistance training recommended.

!

Psychiatric Effects

4 mentions

Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.

!

Hair Loss

3 mentions

May occur with rapid weight loss. Usually temporary (telogen effluvium). Ensure adequate nutrition.

i

Gastrointestinal Issues

71 mentions

GI side effects are the most commonly reported. Usually improve over time with slow titration.

i

Injection Site Reactions

21 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose
0.25mg weekly
Titration
Increase every 4 weeks: 0.25→0.5→1→1.7→2.4mg
Half-life
~7 days
Administration
Subcutaneous injection (Ozempic/Wegovy) or oral (Rybelsus), once weekly

Community Dosing Patterns

Based on 411 mentions

Community-reported patterns, not medical advice.

0.25mg weekly
20
1mg weekly
19
0.5mg weekly
16
2.4mg weekly
15
weekly
12

Pricing

Research-grade reference pricing for 10mg vial. Prices vary by vendor and quantity.

We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.

US Research Grade

$75

Single small vial from US domestic vendors

US Research Grade (Bulk)

$64

Per-dose equivalent when buying larger US vials

China Research Grade

$3.67

Per-vial when buying 10-pack from Chinese vendors

95% savings

Research

1,345
Total Articles
621
Clinical Trials
414
Reviews

Key Studies

Legume-Derived Bioactive Peptides in Type 2 Diabetes: Opportunities and Challenges Review

Nutrients (2023)

Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice Preclinical

Physiol Rep (2023)

Semaglutide in renal ischemia-reperfusion injury in mice Preclinical

J Med Life (2023)

Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects Clinical Trial

Clin Pharmacokinet (2023)

In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A Method Using Existing in silico Algorithm Infrastructure and a Vision for Future Enhancements Preclinical

Front Drug Discov (Lausanne) (2022)

Commonly Stacked With

Based on 1,248 community posts mentioning Semaglutide.

Tirzepatide 352 mentions (28.2%)
Retatrutide 228 mentions (18.3%)
Cagrilintide 55 mentions (4.4%)
BPC-157 22 mentions (1.8%)
TB-500 19 mentions (1.5%)

Switching Patterns

Based on 171 discussions about switching to or from Semaglutide.

→ Switching FROM

Tirzepatide 15 mentions
Retatrutide 11 mentions

Users who switched to Semaglutide

← Switching TO

Retatrutide 27 mentions
Tirzepatide 26 mentions

Users who switched from Semaglutide

Frequently Asked Questions

What is semaglutide and how does it work?

Does semaglutide help with weight loss?

Which is more effective for weight loss: tirzepatide or semaglutide?

Does semaglutide reduce food noise?

Does semaglutide help with insulin resistance?